Biotech company collaborated with Zemoso to co-create a solution to fully automate the manufacturing of induced pluripotent stem cell (iPSC)-based cell therapies, making personalized stem cell-derived therapies scalable and accessible.
Manual intervention in cell manufacturing - a biologist examining cells by eye and removing unacceptable ones by pipette - introduces operator variability and makes it hard to deliver stem-cell-based therapies affordably at scale. Cellino needed an interactive web application that could present cell manufacturing data like high-resolution microscopy images, give investors and the advisory board a tangible sense of the idea, and accelerate the MVP launch of its research-grade stem cell manufacturing platform on a time-boxed schedule.
We partnered with Cellino to integrate the external lab instrument controller systems and front-end action items with a constantly improving AI engine, and to build an Automation Information Management System (AIMS) to represent all data generated from the manufacturing processes of many cell lines. This system would be a listener and viewer for the colossal amounts of data captured, analyzed, and sent over by their instrumentation as well as the Artificial Intelligence (AI)/Machine Learning (ML) core. AIMS helped biologists monitor cell manufacturing processes in the following ways:
By building AIMS as a fast, web-optimized viewer for massive, multi-channel microscopy data, Zemoso gave Cellino's biologists a way to examine and annotate cell clusters in milliseconds - turning a research-grade prototype into a tool that could support both scientific decision-making and investor conversations.